Jerry Bagel, M.D.

The Numbers on My Parents’ Arms
Buy Now

NPF Excellence in Leadership
Award Recipient, 2018

Dr Bagel NPF Award

Board Certified Dermatologist Specializing in Psoriasis Treatment in East Windsor, NJ

Dr. Bagel is a nationally recognized expert in the treatment of psoriasis and is regularly invited to speak across the country and internationally about this medical condition and its treatment. Dr. Bagel has been named a Top Doctor in the Castle Connolly Medical Top Doctors of the New York Metro Area every year from 2001-2015. He was named a 2005 New Jersey Top Doctor by New Jersey Life; a Best Doctor in New Jersey by New Jersey Monthly in 2001 and 2003; and received a Patients’ Choice award in 2008 as well as in Inside Jersey in 2013 and 2015. He is a four term member of the medical advisory board of the National Psoriasis Foundation. Dr. Bagel is an Editor of Practical Dermatology and the Assistant Editor of Psoriasis Forum. He has published extensively on the topic of psoriasis in such journals as The Journal of the American Academy of Dermatology and The Journal of Drugs & Dermatology. Dr. Bagel loves spending his free time at the beach, watching the Mets and enjoying great cuisine!


  • Board certified in dermatology
  • Psoriasis and Eczema expert
  • Fellow of the American Academy of Dermatology
  • Education: Bachelor of Arts, Boston University; Master of Science, Rutgers University; Doctor of Medicine, Mount Sinai School of Medicine
  • Internship in Internal medicine: University of Miami-Jackson Memorial Hospital
  • Residency in dermatology: College of Physicians and Surgeons, Columbia University
  • Practicing dermatology and dermatologic surgery for over 35 years
  • Senior Attending Physician at Penn Medicine Princeton Health


  • 2017 Bagel, J. & Stein Gold, L.  Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy Regimens:  A Review of the Literature. JDD 2017; 16 pp 611-624.
  • 2017 Bagel, J. et al. Secukinumab moderate to severe psoriasis on scalp:  JAAD. 2017; 77 pp 659-667.
  • 2017 Bagel, J, Callis Duffin, K, Moore, A, Ferris, L. K., Siu, K, Steadman, J, Kianifard, F., Nyirady, J., Lebwohl, M.  The Effect of Secukinumab on Moderate-to-Severe Scalp Psoriasis: Results of a 24-Week, Randomized, Double-blind, Placebo-controlled Phase 3b Study. J Am Acad Dermatol. 2017 Oct. Vol 77, Issue 4 pp 667-674.
  • 2017 Strober, B, Bagel. J, Lebwohl, M, et al.  Efficacy and Safety of Apremilast in patients with moderate psoriasis and lower BSA:  UNVEIL study.  JDD 2017 Vol 16,28 pp 801-808.
  • 2017 Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, Iles J, Stolshek BS, Kaliyaperumal A, Papp KA. Open-label study of etanercept treatment in patients with moderate to severe plaque psoriasis who lost a satisfactory response to adalimumab. Br J Dermatol. 2017 Feb 14. doi: 10.1111/bjd.15381.
  • 2017 Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.   J Drugs Dermatol. 2017;16(2):147-153.
  • 2017 Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28.
  • 2017 Callis Duffin K, Bagel J, Bukhalo M, Mercado Clement IJ, Choi SL, Zhao F, Gill A, Pangallo B, Shuler C, Mallbris L, Jackson K. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017 Jan;31(1):107-113. doi: 10.1111/jdv.13768. Epub 2016 Aug 8.







  • 2011 Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011 May;64(5):936-49. doi: 10.1016/j.jaad.2009.12.054. Epub 2011 Mar 22.
  • 2011 Jerry Bagel, M.D.  Adalimumab Plus Narrowband Ultraviolet B Light  Phototherapy for the Treatment of Moderate to Severe Psoriasis, Journal of Drugs in Dermatology, April 2011.


  • 2010 Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E; Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010 Sep;86(3 Suppl):5-31; quiz 32.
  • 2010 Bagel, J.  Treatment of Pediatric Psoriasis: Practical Dermatology, September 2010


  • 2009 Bagel, J.  Topical Therapies for the Treatment of Plaque Psoriasis: Cutaneous Medicine for the Practitioner, Vol. 84, No. 4S pgs. 3-13, October 2009
  • 2009 Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, Van Voorhees AS; National Psoriasis Foundation. Treatment of intertriginous psoriasis: From the Medical Board of National Psoriasis Foundation: J Am Acad Dermatology, 2009 January; 60 (1): pgs. 120-124
  • 2009 Bagel, J. Understanding PML and Risks Associated with Biologic Therapies: Practical Dermatology, Vol. 6, No. 5 pgs. 26-27, May 2009.
  • 2009 Bagel, J. Treatment of Effective Therapy: Lead Psoriasis Patients Along the Path to Clearance, Practical Dermatology ,Vol. 6, No. 2 , pgs. 42-47, February 2009.
  • 2009 Bagel, J. LCD Plus NB-UVB reduces Time to Improvement of Psoriasis vs. NB-UVB Alone, Journal of Drugs in Dermatology, Vol. 8 Issue 4 April 2009.
  • 2009 Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, Van Voorhees AS; Treatment of intertiginous psoriasis: From the Medical Board of the National Psoriasis Foundation,  Journal of the   American Academy of Dermatology, Vol. 60, Issue 1, January, 2009.


  • 2008 Bagel, J. Topical Psoriasis Therapy: Patients’ Experiences, Physicians’ Perceptions Don’t Always Match, Practical Dermatology, Vol. 5, No. 2, pgs 58-61, February, 2008.
  • 2008 Kircik L1, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR; Unite Study Group. Utilization of Narrow-Band Ultraviolet Light B Therapy and Etanercept for the Treatment of Psoriasis (UNITE): Efficacy, Safety, and Patient-Reported Outcomes, Journal of Drugs in Dermatology, January, 2008.
  • 2008 Lebwohl M1, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L.  From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis, Journal of the American Academy of Dermatology, Vol. 58, No. 1 pgs 94-105, January, 2008.


  • 2007 Bagel, J. Be Prepared to Treat Pustular Psoriasis—An Uncommon Variant, Practical Dermatology, Vol. 4, No. 12, pg. 43, December, 2007.
  • 2007 Bagel, J. Choosing the Safest Psoriasis Treatment for Women of Childbearing Potential, Practical Dermatology, Vol. 4, No. 11, pg. 50-51, November, 2007.
  • 2007 Bagel, J. Effective Strategies To Treat Intertriginous Psoriasis, Practical Dermatology, Vol. 4, No. 10, pg. 54-58, October, 2007.
  • 2007 Jerry Bagel, M.D., Responding to the Potential Effects of Obesity on Psoriasis, Practical Dermatology, Vol. 4, No. 9, pg. 46-47, September, 2007.
  • 2007 Bagel, J. Building Long-Term Relationships as a Patient Caregiver, Practical Dermatology, Vol. 4, No. 8, pg. 53-54, August, 2007.
  • 2007 Bagel, J. Get Familiar with the Biologics Safety Dance, Practical Dermatology, Vol. 4, No. 7, pg. 17-18,  July, 2007.
  • 2007 Bagel, J. Guidelines for Use of PUVA and Tips for Success, Practical Dermatology, Vol. 4, No. 6, pg. 56-57, June, 2007.
  • 2007 Bagel, J. Psoriasis Research You and Your Patients Can Take to the Bank, Practical Dermatology, Vol. 4, No. 5, pg. 56-58, May, 2007.
  • 2007 Bagel, J. Exploring Off-Label Use of Biologics for Dermatologic Indications, Practical Dermatology, Vol.4, No.5, pg.56-58. April, 2007.
  • 2007 Bagel, J. et al., Assessment and tracking of long-term alefacept safety, Journal of the American Academy of Dermatology, Vol.56, Issue 2, Supplement 2, February, 2007.
  • 2007 Bagel, J. et al. National Psoriasis Foundation Clinical Consensus on Disease Severity,             Archives of Dermatology, Vol. 143, February, 2007.
  • 2007 Bagel, J. Evaluating the Risks and Benefits of Soriatane, Practical Dermatology, Vol. 4, No. 2, pg. 82-84, February, 2007.
  • 2007 Bagel, J.  New Perspectives on Methotrexate and Liver Biopsies, Practical Dermatology, Vol. 4, No. 1, pg. 74-75, January, 2007.


  • 2006 Bagel, J.  How and When to Use Cyclosporine in Psoriasis Care, Practical Dermatology,  Vol..3, No. 12., pg. 58-61, December, 2006.
  • 2006 Bagel, J. Practical Dermatology: In the Pipeline: Promising Early Data for a New Biologic.  November, 2006: 3:11 pg. .25-26.
  • 2006 Bagel, J.  Practical Dermatology: Approaches to Difficult-to-Treat Psoriasis in  Specialized Areas. October, 2006: 3:10 pg 48-50.
  • 2006 Koo JY, Bagel J, Sweetser MT, Ticho BS. Journal of Drugs in Dermatology, Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study ( the “Manuscript”).  July/August, 2006
  • 2006 Bagel, J.  Unlock the Benefits of Phototherapy for Psoriasis: Practical Dermatology, April, 2006: pg. 41    


  • 2005 Bagel, J.  Psoriasis Combination Therapy: Psoriasis Forum
  • 2005 Bagel, J.  Decision points for the initiation of systemic treatment for psoriasis: Journal of the American Academy of Dermatology, 53:101, 2005
  • 2005 Bagel, J.  Chordoma Cutis: Journal of the American Academy of Dermatology, 52:S105, 2005


  • 2002 Lowe NJ, Gonzalez J., Bagel, J., et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003;42:224-230.
  • 2002 Bagel, J.  A guide to Introducing Biologic Therapies for Psoriasis into Clinical Practice:  Precept Medical Communications


  • 2001  Ellis CN, Krueger GG; Alefacept Clinical Study Group.. Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes:  New England Journal of Medicine, 345:248, 2001


  • 1999 Bagel, J. Establishing a Practical and Effective Psoriasis Treatment Center:  Dermatologic Clinics of North America, April, 2000


  • 1998 Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J. Administration of DAB389IL-2 to patients with recalcitrant psoriasis:  A double-blind, phase II multicenter trial; Journal of American Academy of Dermatology, 38:938, 1998


  • 1985 Bagel, J. Subcutaneous Nodules in Pseudomas Septicemia; American Journal of Medicine, 80:528, 1986
  • 1985 Bagel, J. Hemorrhagic Bullae Associated with Morganella Morganii Septicemia; Journal of the American Academy of Dermatology, 12:575, 1985
  • 1985 Bagel, J. Wavelength Dependence for 4’, 5’ – Monoadduct Formulation in UVA Irradiated 8-Methoxypsoralen and Calf Thymus DNA; Photochemistry and Photobiology, 42:95, 1985
Jerry Bagel, MD, MS: Bimekizumab shows rapid, effective treatment of plaque psoriasis

Read full article here >>

Jerry Bagel: Addressing Comorbidities in Plaque Psoriasis

Read full article here >>

Jerry Bagel, MD: Starting the Treatment Process for Plaque Psoriasis

Read full article here >>

Jerry Bagel: Approaching Psoriasis Treatment Based on Location

Read full article here >>

Jerry Bagel, MD: Evolution of Psoriasis Treatment Means Better Results for Patients

Read full article here >>

Research in Eczema Is Lacking, Despite Progress in Psoriasis

Read full article here >>

Jerry Bagel, MD, from the Psoriasis Treatment Center of Central New Jersey: Moving Beyond Tar and Lights in Treatment of Plaque Psoriasis

Read full article here >>

Jerry Bagel, MD, Explains How to Measure Success in Psoriasis Treatment

Read full article here >>

Translate »